Physician profile
William King
NPI 1467433961
$1,622.63
in general payments reported to CMS, 2019-2025
15 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $13.64 · 2022: $89.00 · 2023: $349 · 2024: $396 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $537.15 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $206.60 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $185.80 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $164.33 | 2019-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $135.43 | 2023-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $113.84 | 2023-2025 | |
| Nxstage Medical, INC. | $65.48 | 2019 | |
| Mallinckrodt Hospital Products INC. | $50.08 | 2023-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $40.91 | 2022-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $26.80 | 2025 | Tarpeyo |
| Daiichi Sankyo INC. | $22.17 | 2019 | |
| Opko Pharmaceuticals, LLC | $22.11 | 2024 | Rayaldee |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.62 | 2024 | Jynarque |
| Boston Scientific Corporation | $17.50 | 2024 | |
| Lilly USA, LLC | $16.81 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.